TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21055582

Group type: EXPERIMENTAL
Intervention: Fixed orthodontic treatment with chemically cured resin
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Fixed orthodontic treatment with light-cured resin
Number of subjects: 26
Study: 17986056

Group type: EXPERIMENTAL
Intervention: Low-dose UVA1 phototherapy (40 J/cm²), 3 times weekly for 14 weeks
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (untreated hand)
Number of subjects: 9
Study: 16179665

Group type: EXPERIMENTAL
Intervention: Modafinil split doses
Number of subjects: 56

Group type: COMPARATOR
Intervention: Modafinil once-daily (200 mg)
Number of subjects: 56
Study: 12487756

Group type: EXPERIMENTAL
Intervention: Medication plus 1 g/day Spirulina (group II)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Medication (group I)
Number of subjects: 23
Study: 9808548

Group type: EXPERIMENTAL
Intervention: DHAP (2 courses)
Number of subjects: 215

Group type: COMPARATOR
Intervention: BEAC followed by ABMT
Number of subjects: 215

Group type: COMPARATOR
Intervention: DHAP (4 additional courses)
Number of subjects: 215

Group type: COMPARATOR
Intervention: BEAC
Number of subjects: 215
Study: 7621847

Group type: EXPERIMENTAL
Intervention: Diltiazem formulation 1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Diltiazem formulation 2
Number of subjects: 20
Study: 2196108

Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum (CP) plus chemotherapy (l-phenylalanine mustard (L-PAM) and 5-fluorouracil (PF))
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone (l-phenylalanine mustard (L-PAM) and 5-fluorouracil (PF))
Number of subjects: 0
Study: 100818

Group type: EXPERIMENTAL
Intervention: Intravenous methylphenidate (0.5 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral methylphenidate (1.0 mg/kg)
Number of subjects: 0
Study: 30799062

Group type: EXPERIMENTAL
Intervention: Video-observed therapy (VOT)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Directly observed treatment (DOT)
Number of subjects: 226
Study: 28962734

Group type: EXPERIMENTAL
Intervention: Combined orthodontic-periodontic treatment
Number of subjects: 117

Group type: COMPARATOR
Intervention: Basic periodontic treatment
Number of subjects: 117

Group type: COMPARATOR
Intervention: Normal group (healthy individuals)
Number of subjects: 117
Study: 25978327

Group type: EXPERIMENTAL
Intervention: Decision aid (three laminated cards with graphics and pros/cons)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 130
Study: 23430315

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (2000 IU daily for 6 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 22174166

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Low fat diet (first control group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No treatment (second control group)
Number of subjects: 120
Study: 19801932

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of L-alanine-L-glutamine dipeptide (0.40 g/kg/d; equal to 0.25 g of free glutamine) in Ala-Glu group (n = 212)
Number of subjects: 428

Group type: COMPARATOR
Intervention: No supplementation in control group (n = 216)
Number of subjects: 428
Study: 16951263

Group type: EXPERIMENTAL
Intervention: Exercise training (ET) in Group A, enrolled in a 3-month exercise-based cardiac rehabilitation (CR) programme.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (Group B) with generic instructions to continue physical activity.
Number of subjects: 40
Study: 14716846

Group type: EXPERIMENTAL
Intervention: HB vaccination (0, 1, 6 month regimen)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no HBV markers)
Number of subjects: 44
Study: 11606013

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous-intensity exercise program (16 weeks, 3 days/week, 30 min/day at approximately 80% of heart rate reserve)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (non-exercising)
Number of subjects: 11
Study: 10481381

Group type: EXPERIMENTAL
Intervention: Heart rate variability test in patients with advanced PD
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Heart rate variability test in patients with early PD
Number of subjects: 22

Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 22
Study: 7956268

Group type: EXPERIMENTAL
Intervention: Participation in the SOLVD trial
Number of subjects: 3522
Study: 3307282

Group type: EXPERIMENTAL
Intervention: Sliding screw plate
Number of subjects: 104

Group type: COMPARATOR
Intervention: 4 ASIF cancellous bone screws
Number of subjects: 104
Study: 29976501

Group type: EXPERIMENTAL
Intervention: Consolidation chemotherapy (2 cycles of capecitabine and oxaliplatin: capecitabine 1700 mg/m2 per day from day 1 to 14, oxaliplatin 100 mg/m2 on day 1, every 3 weeks) after CRT.
Number of subjects: 110

Group type: COMPARATOR
Intervention: Preoperative chemoradiation therapy (CRT) with capecitabine (50.4 Gy in 28 fractions) followed by TME.
Number of subjects: 110
Study: 27871086

Group type: EXPERIMENTAL
Intervention: Foam cream (active agent)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo foam cream
Number of subjects: 0
Study: 24762588

Group type: EXPERIMENTAL
Intervention: Omeprazole, amoxicillin, and clarithromycin for 1 week (T group)
Number of subjects: 552

Group type: COMPARATOR
Intervention: Placebo (P group)
Number of subjects: 552
Study: 22452326

Group type: EXPERIMENTAL
Intervention: Targeted preload optimisation using a supine stroke volume variation value < 14%
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Patients with low supine stroke volume variation
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Patients with high supine stroke volume variation who received volume preload
Number of subjects: 45
Study: 20485956

Group type: EXPERIMENTAL
Intervention: 4 mL of hyperbaric bupivacaine (10 mg) and sufentanil (5 microg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 3 mL of hyperbaric bupivacaine (10 mg) and sufentanil (5 microg)
Number of subjects: 40
Study: 18321585

Group type: EXPERIMENTAL
Intervention: CeeOn (highly refractive index silicone IOL with a sharp optic edge)
Number of subjects: 288

Group type: COMPARATOR
Intervention: AcrySof (acrylic IOL with a sharp optic edge)
Number of subjects: 288

Group type: COMPARATOR
Intervention: PhacoFlex (highly refractive index silicone IOL with a round optic edge)
Number of subjects: 288
Study: 16042023

Group type: EXPERIMENTAL
Intervention: P300 evoked potential analyses of cortical response to acoustic stimulation in the oddball paradigm (AS-Group)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (C-Group)
Number of subjects: 39
Study: 11952807

Group type: EXPERIMENTAL
Intervention: BQ‐123 (60 microg min(‐1)), a specific ETA‐receptor antagonist
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ang II (0.65, 1.25, 2.5, 5 ng kg(‐1) min(‐1) for 15 min per dose level)
Number of subjects: 10
Study: 10732594

Group type: EXPERIMENTAL
Intervention: Kogan's (1961) Attitude Toward Old People's Scale administered before clinical experiences
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Kogan's (1961) Attitude Toward Old People's Scale administered after clinical experiences
Number of subjects: 100
Study: 7677537

Group type: EXPERIMENTAL
Intervention: Steroid regimen: 1 g of methylprednisolone sodium succinate intravenously before bypass and 4 mg of dexamethasone every 6 hours for four doses during the first 24 hours of recovery.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Nonsteroid group (control).
Number of subjects: 19
Study: 2209305

Group type: EXPERIMENTAL
Intervention: Clonidine (0.1 and 0.2 mg/day)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg 3 times/day)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (for both clonidine and pentoxifylline)
Number of subjects: 37
Study: 775954

Group type: EXPERIMENTAL
Intervention: Intravenous digoxin (0.01 mg/kg over 10 minutes)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Intravenous digoxin
Number of subjects: 33
Study: 31282193

Group type: EXPERIMENTAL
Intervention: Mindfulness training (experimental group, n=23)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (n=22)
Number of subjects: 45
Study: 28662677

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) with pembrolizumab (200 mg intravenously, every 3 weeks)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 13
Study: 26295268

Group type: EXPERIMENTAL
Intervention: IVR reminder only
Number of subjects: 12285

Group type: COMPARATOR
Intervention: Postcard reminder only
Number of subjects: 12285

Group type: EXPERIMENTAL
Intervention: Postcard plus IVR reminder
Number of subjects: 12285
Study: 23808756

Group type: EXPERIMENTAL
Intervention: Prescription headache medication
Number of subjects: 551
Study: 21854276

Group type: EXPERIMENTAL
Intervention: Exercise as an augmentation treatment
Number of subjects: 0
Study: 19833592

Group type: EXPERIMENTAL
Intervention: Autologous Hemobag blood transfusion (AHBT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Allogenic blood transfusion (ABT)
Number of subjects: 60
Study: 17108629

Group type: EXPERIMENTAL
Intervention: Multimedia Health Educational Program (MHEP) presented by a Registered Nurse (RN)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Leaflet designed using the exact contents of the MHEP
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Verbal information from the RN
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional preoperative information by the attending surgeon and anesthesiologist (Control Group D)
Number of subjects: 60
Study: 15651513

Group type: EXPERIMENTAL
Intervention: Air
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: N2O + O2
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Saline
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 4% lidocaine
Number of subjects: 80
Study: 11704169

Group type: EXPERIMENTAL
Intervention: Transperitoneal laparoscopic Burch procedure using nonabsorbable sutures (group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Transperitoneal laparoscopic Burch procedure using Prolene mesh (group B)
Number of subjects: 60
Study: 9052291

Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 330

Group type: COMPARATOR
Intervention: Control (no nitrous oxide)
Number of subjects: 330
Study: 8183752

Group type: EXPERIMENTAL
Intervention: Subcutaneous fluid therapy (2 litres of dextrose-saline/24 hours)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Intravenous fluid therapy (2 litres of dextrose-saline/24 hours)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Subcutaneous fluid therapy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Intravenous fluid therapy
Number of subjects: 34
Study: 3070826

Group type: EXPERIMENTAL
Intervention: Ethamsylate (2 g/day in four equal doses)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 31865579

Group type: EXPERIMENTAL
Intervention: Plant-derived compounds with larvicidal activity; specific compounds not detailed
Number of subjects: 263
Study: 29257140

Group type: EXPERIMENTAL
Intervention: Amitriptyline (AMI; 50 mg)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Escitalopram (ESC; 10 mg)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study: 28160761

Group type: EXPERIMENTAL
Intervention: Nartana herbal formulation (450 mg, 2 ×/d for first 15 d, then 1 ×/d)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Diclofenac (50 mg, 2 ×/d for first 15 d, then 100 mg, 1 ×/d)
Number of subjects: 80
Study: 25724974

Group type: EXPERIMENTAL
Intervention: School-based intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 24066262

Group type: EXPERIMENTAL
Intervention: Educational intervention group
Number of subjects: 268

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 268
Study: 21848870

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 18979387

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) over ventral premotor cortex (vPMc)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Event-related rTMS over extrastriate body area (EBA)
Number of subjects: 0
Study: 16918762

Group type: EXPERIMENTAL
Intervention: Dronabinol (DRO) 5 mg b.i.d.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 30
Study: 15598119

Group type: EXPERIMENTAL
Intervention: Monitoring sounds (6 sounds with 5 levels each)
Number of subjects: 6
Study: 11197587

Group type: EXPERIMENTAL
Intervention: Zanamivir 10 mg inhaled twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg orally twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zanamivir 10 mg inhaled once daily for prophylaxis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg orally once daily for prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oseltamivir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zanamivir in patients with asthma or COPD
Number of subjects: 0
Study: 9103722

Group type: EXPERIMENTAL
Intervention: Daily urge intensity measures
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Average duration of temptation episodes
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Urge intensity at waking
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Urge intensity in temptations
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Frequency of temptation
Number of subjects: 214
Study: 7957037

Group type: EXPERIMENTAL
Intervention: Left-sided cervical electrical stimulation at 30 Hz (high stimulation)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Left-sided cervical electrical stimulation at 1 Hz (low stimulation)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Inhaled ipratropium bromide (160 micrograms, dry powder) added to stimulation in one patient with obstructive lung disease
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Variable frequency and current stimulation (10-87 Hz and 0.5-2.5 mA)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intense vagal stimulation in patients with obstructive lung disease
Number of subjects: 14
Study: 3066896

Group type: EXPERIMENTAL
Intervention: Amitriptyline or Imipramine treatment
Number of subjects: 82
Study: 30741862

Group type: EXPERIMENTAL
Intervention: Treadmill training (TM)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Overground training (TR)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (CONTROL)
Number of subjects: 64
Study: 31549943

Group type: EXPERIMENTAL
Intervention: Dynamic CT myocardial perfusion imaging (MPI)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Machine learning (ML)‐based CT fractional flow reserve (FFR)
Number of subjects: 86
Study: 28661170

Group type: EXPERIMENTAL
Intervention: Tablet computer
Number of subjects: 212

Group type: COMPARATOR
Intervention: Paper-and-pencil materials
Number of subjects: 212
Study: 26347440

Group type: EXPERIMENTAL
Intervention: Therapist Brief Intervention (BI)
Number of subjects: 836

Group type: EXPERIMENTAL
Intervention: Computer Brief Intervention (BI)
Number of subjects: 836

Group type: EXPERIMENTAL
Intervention: Post-ED session
Number of subjects: 836

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 836
Study: 23681144

Group type: EXPERIMENTAL
Intervention: Automated alert recommending lung-protective ventilation with a Vt of 6 cc/kg predicted body weight
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 0
Study: 20663568

Group type: EXPERIMENTAL
Intervention: Deep transcranial magnetic stimulation (DTMS) with positive cognitive-emotional reactivation
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Deep transcranial magnetic stimulation (DTMS) with negative cognitive-emotional reactivation
Number of subjects: 57
Study: 19006791

Group type: EXPERIMENTAL
Intervention: Testicular sperm extraction (TESE)
Number of subjects: 62
Study: 17573205

Group type: EXPERIMENTAL
Intervention: Enhanced cognitive-behavioral therapy (MET+CBT)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 74
Study: 15019013

Group type: EXPERIMENTAL
Intervention: PAPNET
Number of subjects: 21747

Group type: EXPERIMENTAL
Intervention: Combined cytology and histology analysis
Number of subjects: 21747
Study: 11579624

Group type: EXPERIMENTAL
Intervention: Naltrexone (100 mg/day)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 183
Study: 9495400

Group type: EXPERIMENTAL
Intervention: ondansetron (0.1 mg/kg, n = 26)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: dimenhydrinate (0.5 mg/kg, n = 25)
Number of subjects: 74

Group type: COMPARATOR
Intervention: placebo (saline, n = 23)
Number of subjects: 74
Study: 7852614

Group type: EXPERIMENTAL
Intervention: 0.1% methylene blue gel irrigated at 0, 1, and 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sterile water irrigation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subgingival debridement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylene blue incorporated into a slow-release device
Number of subjects: 0
Study: 3137835

Group type: EXPERIMENTAL
Intervention: RO 15‐1788
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 30964778

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (1,500 IU/day) for 28 days
Number of subjects: 262
Study: 29309040

Group type: EXPERIMENTAL
Intervention: Mulligan Mobilization with Movement (MWM)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Osteopathic Mobilization (OM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both MWM and OM
Number of subjects: 40
Study: 27659078

Group type: EXPERIMENTAL
Intervention: Tetric‐N‐Flow (nano‐hybrid composite)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Transbond Supreme LV (low viscosity composite)
Number of subjects: 100
Study: 26714784

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) by inflating an upper extremity blood-pressure cuff for 3 x 5 min to 200 mmHg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham group (control)
Number of subjects: 24
Study: 23514036

Group type: EXPERIMENTAL
Intervention: Heme Iron Polypeptide (HIP) 11 mg orally 3 times per day
Number of subjects: 40

Group type: COMPARATOR
Intervention: IV iron sucrose 200 mg monthly for 6 months
Number of subjects: 40
Study: 18158618

Group type: EXPERIMENTAL
Intervention: Pain catastrophizing with high resting lower paraspinal muscle tension
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Pain catastrophizing with low cardiovascular reactivity (SBP, DBP, HR)
Number of subjects: 97
Study: 12511176

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Naltrexone plus Acamprosate
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 10985268

Group type: EXPERIMENTAL
Intervention: Hospitals implementing measurement activities or systematic improvements
Number of subjects: 117

Group type: COMPARATOR
Intervention: All other hospitals in the state (control group)
Number of subjects: 117
Study: 8803505

Group type: EXPERIMENTAL
Intervention: Velodrome test
Number of subjects: 12

Group type: COMPARATOR
Intervention: Laboratory test
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Maximal oxygen uptake (VO2max)
Number of subjects: 12
Study: 1738009

Group type: EXPERIMENTAL
Intervention: Intervention group taught to reduce dietary fat intake to 15% of total calories from a baseline average of 35% of calories.
Number of subjects: 507

Group type: COMPARATOR
Intervention: Control group taught the principles of balanced nutrition without counseling to change fat intake.
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Modified procedure for entry with subjects first taught procedures before consent and randomization.
Number of subjects: 507
Study: 6436182

Group type: EXPERIMENTAL
Intervention: Cefroxadine 250 mg q.i.d. for ten days
Number of subjects: 64

Group type: COMPARATOR
Intervention: Cephalexin 500 mg q.i.d. for ten days
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Cefroxadine
Number of subjects: 64

Group type: COMPARATOR
Intervention: Cephalexin
Number of subjects: 64
Study: 31469303

Group type: EXPERIMENTAL
Intervention: Lixisenatide combined with basal insulin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basal-plus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basal-bolus
Number of subjects: 0
Study: 29271022

Group type: EXPERIMENTAL
Intervention: Weekly supplementation (120 mg elemental iron, 3 mg folic acid, 100 mg vitamin C)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Daily supplementation (60 mg elemental iron, 1 mg folic acid, 100 mg vitamin C)
Number of subjects: 292
Study: 27297850

Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25502755

Group type: EXPERIMENTAL
Intervention: Genome-wide methylated DNA immunoprecipitation sequencing (MeDIP-seq)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Replication in 221 controls
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Integrated genomics and epigenomics approach
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Analysis of T2D-discordant twins
Number of subjects: 54
Study: 22325157

Group type: EXPERIMENTAL
Intervention: 10g/d BSP (group A)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 5g/d BSP (group B)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo (group C)
Number of subjects: 81
Study: 20362977

Group type: EXPERIMENTAL
Intervention: High ruminators
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Low ruminators
Number of subjects: 242

Group type: COMPARATOR
Intervention: Worry (high and low)
Number of subjects: 242
Study: 18827074

Group type: EXPERIMENTAL
Intervention: XP13512 immediate-release (up to 2800 mg single dose and 2100 mg twice daily)
Number of subjects: 136

Group type: COMPARATOR
Intervention: XP13512 extended-release (equimolar dose compared with 600 mg gabapentin)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Oral gabapentin (up to 1200 mg)
Number of subjects: 136